Due to the prognostic value of CD8+ TILs in both the TN and TS, some studies have indicated that patients with surgically resected stage I NSCLC showing a low density of CD8+ TILs could be considered for adjuvant chemotherapy, even if they have no high-risk features [51]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.